ORCHARD THERAPEUTICS PLC - AMERICAN DEPOSITARY SHARES

ORCHARD THERAPEUTICS PLC - AMERICAN DEPOSITARY SHARES

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined ... immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Orchard Therapeutics Plc - American Depositary Shares_logo

Industry:
Company

Address:
108 Cannon Street, London, United Kingdom Zipcode EC4N 6EU

Country:
United Kingdom

Phone:
44 20 3 808 8286

Market Cap:
811.44M
Total Revenue:
2.6M
Total Assets:
280.94M
Total Cash:
55.13M

Founders: Ben Auspitz · Andrea Spezzi


Key Executives
Name Title Pay Year Born
Dr. Bobby Gaspar Ph.D., M.D. CEO, Member of Scientific Advisory Board & Exec. Director 519,473$ 1965(55 years old)
Mr. Frank E. Thomas Pres & COO 691,243$ 1970(50 years old)
Ms. Renee T. Leck Director of Investor Relations N/A N/A
Mr. John Ilett Chief of Staff, Chief Legal Officer & Company Sec. N/A N/A
Molly Cameron Mang. of Corp. Communications N/A N/A
Mr. John Cerio Chief Human Resource Officer N/A N/A
Dr. Anne Dupraz-Poiseau Chief Devel. Officer N/A N/A
Mr. Adrien Lemoine Chief Bus. Officer N/A N/A
Mr. Robin Kenselaar Sr. VP & GM of EMEA Commercial Operations N/A N/A
Mr. Braden Parker Chief Commercial Officer N/A N/A



Financial & Stock
Exchange NasdaqGS. Currency in USD. Market state POSTPOST
According to Orchard Therapeutics Plc - American Depositary Shares's financial reports the company's revenue in 2020 were 2.6M an increase(0%) over the years 2019 revenue that were of 2.51M. In 2020 the company's total earnings were -151.98M while total earnings in 2019 were -163.42M(-7.36%).
Company's stock symbol is ORTX. Lastest price : 6.66. Total volume :386.62k Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.orchard-tx.com

  • Host name: 208.21.184.35.bc.googleusercontent.com
  • IP address: 35.184.21.208
  • Location: United States
  • Latitude: 38.6583
  • Longitude: -77.2481
  • Timezone: America/New_York

Loading ...
Loading ...


More informations about "Orchard Therapeutics Plc - American Depositary Shares" on Search Engine

Orchard Therapeutics plc American Depositary Shares (ORTX)

Nasdaq.com Orchard Therapeutics plc American Depositary Shares (ORTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Orchard Therapeutics plc - American Depositary Shares

Benzinga.com Jan 01, 2010 · Orchard Therapeutics plc - American Depositary Shares ORTX: ... Orchard Therapeutics' MPS-I Gene Therapy Shows Encouraging Action In Early Study, Shares …

SEC Filing - Orchard Therapeutics PLC

Ir.orchard-tx.com Dec 31, 2020 · (1) Comprised of American Depositary Shares (representing a like number of ordinary shares) held by Deerfield Private Design Fund III, L.P. and Deerfield Private Design Fund IV, L.P., of which Deerfield Management Company, L.P. is the investment advisor.

SEC Filing - Orchard Therapeutics PLC

Ir.orchard-tx.com Dec 31, 2019 · Orchard Therapeutics PLC (Name of Issuer) Ordinary Shares, par value £0.10 (represented by American Depositary Shares) (Title of Class of Securities) 68570P101 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

SEC Filing | Orchard Therapeutics

Ir.orchard-tx.com ORCHARD THERAPEUTICS PLC (Name of Issuer) Ordinary Shares, par value £0.10 (represented by American Depositary Shares) (Title of Class of Securities) 68570P101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

SEC Filing | Orchard Therapeutics

Ir.orchard-tx.com ORCHARD THERAPEUTICS PLC (Name of Issuer) Ordinary Shares, par value £0.10 (represented by American Depositary Shares) (Title of Class of Securities) 68570P101 (CUSIP Number) March 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Orchard Therapeutics plc (ORTX) Stock Price, News, Quote

Finance.yahoo.com Find the latest Orchard Therapeutics plc (ORTX) stock quote, history, news and other vital information to help you with your stock trading and investing.

ORTX Stock - Orchard Therapeutics Plc SEC Filings

Sec.report Orchard Therapeutics plc is regulated by the U.S. Security and Exchange Commission and incorporated in the state of United Kingdom. Orchard Therapeutics plc is primarely in the business of biological products (no diagnostic substances). ... Orchard Therapeutics / Orchard Therapeutics plc American Depositary Shares: GB XNAS: ORTX ...

SEC Filing - ORCHARD THERAPEUTICS PLC

Ir.orchard-tx.com ORCHARD THERAPEUTICS PLC (Name of Issuer) Ordinary Shares, par value £0.10 (represented by American Depositary Shares) (Title of Class of Securities) 68570P101 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement)

SEC Filing | Orchard Therapeutics

Ir.orchard-tx.com Nov 02, 2018 · The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Ordinary Shares, par value £0.10 (represented by American Depositary Shares) of Orchard Therapeutics PLC shall be filed on behalf of the undersigned.

Orchard Therapeutics

Orchard-tx.com “In this Cell & Gene article, Orchard co-founder and CMO Andrea Spezzi reflects on the meaning of our work in gene therapy and what drives her: https://bit.ly/37jkQ7i #RareDiseaseDay @_CellandGene“ “Orchard is incredibly honored to be the recipient of the 2021 @eurordis Company Award for Innovation. #EURORDISAwards2021“

SEC Filing | Orchard Therapeutics

Ir.orchard-tx.com Form of Deposit Agreement, by and among Orchard Therapeutics plc (the “ Company ”), Citibank, N.A., as depositary (the “ Depositary ”), and all Holders and Beneficial Owners of American Depositary Shares issued thereunder (“ Deposit Agreement ”).

Orchard Therapeutics plc American Depositary Shares (ORTX)

Nasdaq.com Mar 03, 2021 · Find the latest press releases from Orchard Therapeutics plc American Depositary Shares (ORTX) at Nasdaq.com.

Orchard Therapeutics plc American Depositary Shares (ORTX)

Nasdaq.com Find the latest Institutional Holdings data for Orchard Therapeutics plc American Depositary Shares (ORTX) at Nasdaq.com.

Orchard Therapeutics plc American Depositary Shares (ORTX)

Nasdaq.com Find the latest Earnings Report Date for Orchard Therapeutics plc American Depositary Shares (ORTX) at Nasdaq.com.

Orchard Therapeutics plc - ADR Stock Forecast: down to 2

Walletinvestor.com Orchard Therapeutics plc - ADR () Stock Market info Recommendations: Buy or sell Orchard Therapeutics stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Orchard Therapeutics share forecasts, stock quote and buy / sell signals below.According to present data Orchard Therapeutics's ORTX shares and potentially its market environment have been in …

Orchard Therapeutics plc 10-Q May. 7, 2020 4:03 PM

Seekingalpha.com ORCHARD THERAPEUTICS PLC ... American Depositary Shares, each representing one ... Net loss per share attributable to ordinary shareholders, basic and diluted $

Ratings | Benzinga

Benzinga.com Jan 01, 2010 · Orchard Therapeutics plc - American Depositary Shares (ORTX) 6.82 -0.28 (-3.94%) Analyst Ratings . Find Analyst Ratings for: Date Research Firm Action Current PT; 4/01/20 ...

Orchard Therapeutics plc Share Price ADR EACH REPR 1 ORD

Hl.co.uk The latest Orchard Therapeutics plc ADR EACH REPR 1 ORD SHS SPON share price. View recent trades and share price information for Orchard Therapeutics plc ADR EACH REPR 1 ORD SHS SPON

ORTX - Stock quote for ORCHARD THERAPEUTICS PLC - MSN …

Msn.com Orchard Therapeutics plc American Depositary Shares (ORTX) Nasdaq 8/7/2020 How an East Bay site may lead a biotech manufacturing revolution

ORTX Stock Price Quote & News - Orchard Therapeutics

Robinhood.com Orchard Therapeutics plc American Depositary Shares, also called Orchard Therapeutics, is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease ...

Orchard Therapeutics plc Approximately $128 Million Follow

Davispolk.com Jun 10, 2019 · Orchard Therapeutics plc Approximately $128 Million Follow-On Offering 6/10/2019 Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the approximately $128 million follow-on offering by Orchard Therapeutics plc of 9,000,000 American Depositary Shares, each representing one ordinary share.

Stock Summary - TD Ameritrade

Research.tdameritrade.com Company profile. Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to …

(ORTX) Call Put Options | Nasdaq

Nasdaq.com See All Market Activity. News + Insights. CLOSE

ORTX SEC Filings - Orchard Therapeutics plc - Annual

Fintel.io EX-1.2 Exhibit 1.2 ORCHARD THERAPEUTICS PLC $100,000,000 AMERICAN DEPOSITARY SHARES EACH REPRESENTING ONE ORDINARY SHARE (NOMINAL VALUE £0.10 PER SHARE) SALES AGREEMENT February 27, 2020 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Orchard Therapeutics plc, a public limited company …

Orchard Therapeutics plc - American Depositary Shares

Nordnet.fi Osta osaketta Orchard Therapeutics plc - American Depositary Shares (ORTX). Nordnetissä voit käydä kauppaa edullisin hinnoin. Klikkaa tästä ja katso reaaliaikainen osakekurssi

ortx-ex21_206.htm - SEC

Sec.gov DEPOSIT AGREEMENT. DEPOSIT AGREEMENT, dated as of November 2, 2018, by and among (i) Orchard Therapeutics plc, a public limited company incorporated under the laws of England and Wales, and its successors (the “Company”), (ii) CITIBANK, N.A., a national banking association organized under the laws of the United States of America (“Citibank”) acting in its capacity as depositary…

Orchard Therapeutics plc - American Depositary Shares

Nordnet.dk Køb Orchard Therapeutics plc - American Depositary Shares (ORTX) aktien. Hos Nordnet kan du handle fra 0 kr. i kurtage. Klik her for at følge aktiekursen i realtid

ORTX | Orchard Therapeutics PLC ADR Stock Price & News - WSJ

Wsj.com View the latest Orchard Therapeutics PLC ADR (ORTX) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Silence Therapeutics Appoints Mark Rothera as President

Globenewswire.com Sep 14, 2020 · Under his leadership, Orchard completed an initial public offering of American Depositary Shares on the Nasdaq Global Market and during his …

EX-5.3

Sec.gov Orchard Therapeutics plc . ... The Prospectus Supplement relates to the registration for the issue and sale by the Company of American depositary shares (“ADSs”), each ADS representing one ordinary share at a nominal value of £0.10 per share (the “Ordinary Shares” and together with the ADSs, ...

EX-5.1 - SEC

Sec.gov Orchard Therapeutics plc – Registration Statement on Form F-1 – Exhibit 5.1 . We have acted as English legal advisers to Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the “Company”) in connection with the proposed offering of American Depositary Shares ...

Orchard Therapeutics prices IPO at $14 per ADS - MarketWatch

Marketwatch.com Oct 31, 2018 · Orchard Therapeutics PLC ORTX, -1.28% priced its initial public offering at $14 per American Depositary Share. The biotech that specializes in ex vivo gene therapies sold 14.3 million shares …

EX-5.1 - SEC.gov | HOME

Sec.gov Orchard Therapeutics plc – Registration Statement on Form F-1 – Exhibit 5.1 . We have acted as English legal advisers to Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the “Company”) in connection with the proposed offering of American Depositary Shares ...

ortx-8k_20200203.htm - SEC

Sec.gov Feb 03, 2020 · ORCHARD THERAPEUTICS PLC (Exact name of Registrant as Specified in Its Charter) ... (or American Depository Shares (“ADSs”) equal to that number of ordinary shares) with an exercise price equal to the closing price of the Company’s ADSs on the Nasdaq Global Select Market on February 3, 2020. The shares subject to the option vest in equal ...

Orchard Therapeutics Announces Pricing of Initial Public

Globenewswire.com Oct 31, 2018 · BOSTON and LONDON, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics plc (Nasdaq: ORTX), a biopharmaceutical company dedicated to transforming the lives of patients with serious and life ...

Orchard Therapeutics Announces Pricing of Initial Public

Biospace.com Oct 31, 2018 · Orchard Therapeutics plc (Nasdaq: ORTX), today announced the pricing of its initial public offering in the United States of 14,285,715 American Depositary Shares (“ADSs”) representing 14,285,715 ordinary shares at an initial public offering price of $14.00 per ADS, before underwriting discounts and commissions.

Orchard Therapeutics plc’s $128 Million Follow-On Offering

Globallegalchronicle.com Orchard Therapeutics plc’s $128 Million Follow-On Offering June 14, 2019 Ambrogio Visconti Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the approximately $128 million follow-on offering by Orchard Therapeutics plc of 9,000,000 American Depositary Shares, each representing one ...

Orchard Therapeutics plans $172.5 million U.S. IPO

Marketwatch.com Oct 05, 2018 · Orchard Therapeutics is seeking to raise up to $172.5 million from a planned stock offering in the U.S., according to a regulatory filing. The U.K. …

Orchard Rx LTD - Law Insider

Lawinsider.com View Orchard Rx LTD contracts and agreements from SEC filings. Including company executives, business partners, clauses and more.

ORTX SEC Filings - Orchard Therapeutics plc - Annual

Fintel.io SC 13G/A - ORTX / Orchard Therapeutics plc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment 02-16 sec.gov UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ORCHARD THERAPEUTICS PLC (Name of Issuer) Ordinary Shares, par value £0.10 (represented by American Depositary Shares…

EX-5.1 - SEC

Sec.gov 1 November 2019 . Orchard Therapeutics plc . 108 Cannon Street . London, EC4N 6EU . Ladies and Gentlemen: Orchard Therapeutics plc—Registration Statement on Form F-3—Exhibit 5.1 . We have acted as English legal advisers to Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the “Company”) in connection with the preparation and filing on the date hereof ...

Automatic Shelf Registration Statement of Securities of

Ih.advfn.com Apr 08, 2021 · (1) Consists of (a) 20,900,321 ordinary shares represented by American Depositary Shares, or ADSs, each representing one ordinary share, and (b) 3,215,434 ordinary shares issuable upon the redesignation of 3,215,434 Non-Voting Ordinary Shares, nominal value £0.10 per share, and represented by ADSs. Pursuant to Rule 416(a) of the Securities Act of 1933, as amended, this …

Ra Capital Management, L.p. ownership in ORTX / Orchard

Fintel.io ORTX / Orchard Therapeutics plc / RA Capital Management, LLC - SC 13G Passive Investment. 2019-02-14 sec.gov - 4 - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ORCHARD THERAPEUTICS PLC (Name of Issuer) Ordinary Shares, par value £0.10 (represented by American Depositary Shares…